Æterna Zentaris Inc. announced at its annual meeting of shareholders held on May 8, 2013, shareholders approved, ratified and confirmed the amendments to the corporation's by-law one.

Æterna Zentaris Inc. Presents at Bloom Burton & Co Healthcare Investor Conference, May-22-2013 10:30 AM. Venue: Toronto Board of Trade, 1 First Canadian Place, Toronto, ON M5X 1C1, Canada. Speakers: Dennis Turpin, Chief Financial Officer and Senior Vice President.

Æterna Zentaris Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported revenues of $16,599,000 compared to $9,510,000 a year ago. The increase is largely attributable to comparative higher deliveries of Cetrotide to certain customers and to the recognition of unamortized deferred revenues related to upfront payments received from its licensee partners in connection with perifosine, following the company's decision to discontinue the Phase 3 trials of perifosine. Loss from operations was $280,000 compared to $6,788,000 a year ago. Income before income taxes was $1,886,000 compared to loss before income taxes of $11,451,000 a year ago. Net income was $1,886,000 or $0.07 per basic and diluted share compared to net loss of $11,451,000 or $0.65 per basic and diluted share a year ago. The significant increase in net income is due largely to the significant increases in license fees revenues (non-cash) and in net finance income (non--cash), as well as to lower net R&D costs, partly compensated by higher SG&A. Cash flows used in its operating activities were $5.9 million, compared to $8.4 million of cash flows used during the same period in 2012. The decrease in its cash used in operating activities is mainly related to lower disbursement with respect to its R&D activities, as well as to lower accounts payable and income tax settlements.